Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR103 (Immune Response BioPharma, Inc.)
- Development stage
- Unknown
- Lead developer
- Immune Response BioPharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
IR103 is an investigational therapeutic vaccine combination consisting of Remune (an inactivated, gp120-depleted HIV-1 immunogen) and Amplivax (a synthetic double-stranded RNA adjuvant). Developed by Immune Response BioPharma, it is designed to stimulate a cell-mediated immune response against HIV-1 in infected individuals, particularly those on antiretroviral therapy (ART). The vaccine aims to enhance HIV-specific immunity, potentially leading to a reduction in viral load and improvements in CD4+ and CD8+ T-cell counts. IR103 has been evaluated in Phase III clinical trials for the treatment of HIV/AIDS.
- Other names
- Remune + Amplivax
02
Targets
BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)HIV-1 antigensTLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on IR103 (Immune Response BioPharma, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IR103 (Immune Response BioPharma, Inc.).